Moxifloxacin
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (6) | US (FDA) | AVELOX IN SODIUM CHLORIDE 0.8% IN PLASTIC CONTAINER | — | 2003-02-28 – 2016-09-27 | fda.gov ↗ |
| Approved | US (FDA) | AVELOX | — | 1999-12-10 | fda.gov ↗ |
Trials 264 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1136 trials | ||||||
| Phase 1 | NCT07422298 | Feb → Jun 2026 overdue | — | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1 | NCT07305831 | Jan → Apr 2026 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT07229157 | Oct 2025 → Aug 2026 overdue | obesity disorder | Amgen | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07063238 | Aug → Dec 2025 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT07023029 | Jun → Sep 2025 | sickle cell disease, thalassemia | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 1 | NCT06846866 | Feb → Oct 2025 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT06746402 | Feb → Sep 2025 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT06589726 | Sep → Dec 2024 | — | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Completed | No outcome recorded |
| Phase 1 | NCT06601192 | Jul 2024 → Feb 2025 | respiratory syncytial virus infectious disease | Enanta Pharmaceuticals, Inc | Completed | No outcome recorded |
| Phase 1 | NCT06258265 | Apr → Jun 2024 | — | Takeda | Completed | No outcome recorded |
| Show all 136 trials opens the full record — a long page | ||||||
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06681688 | Jul 2024 → Jun 2025 overdue | cataract | Inder Paul Singh, M.D. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT00396084 | Feb 2004 → Nov 2007 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 226 trials | ||||||
| Phase 2 | NCT07485010 | Apr 2027 → Apr 2031 expected | pulmonary non-tuberculous mycobacterial infection | The University of Queensland | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07595042 | Jul 2026 → Jun 2029 expected | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07227779 | Jul 2026 → Aug 2030 expected | meningeal tuberculosis | University of Minnesota | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07129629 | Aug 2025 → Dec 2026 expected | pulmonary tuberculosis | Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06917495 | Apr 2025 → Dec 2027 expected | tuberculosis, spinal | Shandong University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07559149 | Jul 2024 → Feb 2025 | corneal ulcer | Gadjah Mada University | Completed | No outcome recorded |
| Phase 2 | NCT06114628 | Jan 2024 → Feb 2027 expected | pulmonary tuberculosis | University College, London | Recruiting | No outcome recorded |
| Phase 2 | NCT05807399 | Apr 2023 → Oct 2027 expected | pulmonary tuberculosis | Michael Hoelscher | Recruiting | No outcome recorded |
| Phase 2 | NCT05382312 | Jul 2022 → May 2025 | tuberculosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT04204122 | Jun 2020 → Mar 2025 | graft versus host disease | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 2 | NCT03405168 | Jan → Jul 2018 | breast cancer | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 2 | NCT02371681 | Feb 2015 → Sep 2017 | pulmonary tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT02193776 | Oct 2014 → Feb 2016 | tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 2 | NCT02595359 | Jan 2013 → Jun 2018 | endophthalmitis | Federal University of Pernambuco | Completed | No outcome recorded |
| Phase 2 | NCT01498419 | Mar 2012 → Apr 2013 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 2 | NCT01238783 | Jan → Dec 2011 | bacterial conjunctivitis | Alcon Research | Withdrawn | No outcome recorded |
| Phase 2 | NCT01158755 | Oct 2010 → Dec 2011 | meningeal tuberculosis | Padjadjaran University | Completed | No outcome recorded |
| Phase 2 | NCT01215851 | Oct 2010 → May 2011 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 2 | NCT01017731 | Nov 2009 → Apr 2010 | cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00728507 | Nov 2009 → Apr 2013 | tuberculosis | Johns Hopkins University | Terminated | No outcome recorded |
| Phase 2 | NCT00458900 | Jul 2007 → Sep 2012 | pneumonia | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 2 | NCT00144417 | Feb 2006 → Jun 2007 | tuberculosis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2 | NCT00306319 | Jan → May 2006 | tuberculosis | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00082173 | Oct 2004 → Sep 2007 | tuberculosis | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT00164463 | Jul 2004 → Aug 2007 | tuberculosis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2 | NCT00140309 | Jul 2003 → Dec 2005 | pulmonary tuberculosis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 2/38 trials | ||||||
| Phase 2/3 | NCT06441006 | Oct 2025 → Aug 2031 expected | multidrug-resistant tuberculosis, pulmonary tuberculosis | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05766267 | Nov 2023 → Dec 2026 expected | pulmonary tuberculosis | Centers for Disease Control and Prevention | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT04207112 | Oct 2020 → Aug 2022 | extensively drug-resistant tuberculosis, multidrug-resistant tuberculosis, pulmonary tuberculosis | Medecins Sans Frontieres, Netherlands | Completed | No outcome recorded |
| Phase 2/3 | NCT04310930 | Mar 2020 → Jun 2029 expected | pulmonary non-tuberculous mycobacterial infection | The University of Queensland | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04879030 | Jan → Aug 2020 | chronic obstructive pulmonary disease | Haiphong University of Medicine and Pharmacy | Completed | No outcome recorded |
| Phase 2/3 | NCT04081077 | Aug 2019 → Sep 2022 | extensively drug-resistant tuberculosis, multidrug-resistant tuberculosis, pulmonary tuberculosis | Medecins Sans Frontieres, Netherlands | Unknown | No outcome recorded |
| Phase 2/3 | NCT03338621 | Jul 2018 → Jul 2021 | multidrug-resistant tuberculosis, pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 2/3 | NCT02589782 | Jan 2017 → Aug 2022 | extensively drug-resistant tuberculosis, multidrug-resistant tuberculosis, pulmonary tuberculosis | Medecins Sans Frontieres, Netherlands | Completed | No outcome recorded |
| Phase 342 trials | ||||||
| Phase 3 | NCT07274020 | Dec 2025 → Dec 2026 expected | bronchiectasis | Assiut University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07268664 | Dec 2025 → May 2028 expected | pulmonary tuberculosis, rifampicin-resistant tuberculosis | Beijing Chest Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07209761 | Oct 2025 → May 2027 expected | pulmonary tuberculosis | Otsuka Pharmaceutical Development & Commercialization, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05821478 | May 2025 → Feb 2027 expected | hidradenitis suppurativa | Institut Pasteur | Recruiting | No outcome recorded |
| Phase 3 | NCT06253715 | Jan 2025 → Sep 2027 expected | lymph node tuberculosis, pulmonary tuberculosis | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 3 | NCT05917340 | Mar 2024 → Sep 2027 expected | meningeal tuberculosis | Indian Council of Medical Research | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05575518 | Aug 2023 → Dec 2025 | HIV infectious disease, tuberculosis | Stellah Mpagama | Unknown | No outcome recorded |
| Phase 3 | NCT02590523 | Jan 2023 → Jan 2024 | cataract, endophthalmitis | Panhandle Eye Group, LLP | Suspended | No outcome recorded |
| Phase 3 | NCT05081401 | May 2022 → Dec 2026 expected | extensively drug-resistant tuberculosis, multidrug-resistant tuberculosis, rifampicin-resistant tuberculosis | Huashan Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT05114720 | Nov 2021 → Nov 2025 | breast cancer | Sun Yat-sen University | Completed | No outcome recorded |
| Phase 3 | NCT04856644 | Jan 2020 → Dec 2023 overdue | pulmonary tuberculosis | Kaohsiung Veterans General Hospital. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03491995 | Apr 2018 → Apr 2023 | Helicobacter pylori infectious disease | Tanta University | Unknown | No outcome recorded |
| Phase 3 | NCT02754765 | Dec 2016 → Jun 2023 | multidrug-resistant tuberculosis, pulmonary tuberculosis | Doctors Without Borders | Completed | No outcome recorded |
| Phase 3 | NCT02563327 | May 2016 → Aug 2021 | tuberculosis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | No outcome recorded |
| Phase 3 | NCT02410772 | Jan 2016 → Jul 2020 | tuberculosis | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 3 | NCT02342886 | Feb 2015 → Jan 2018 | multidrug-resistant tuberculosis, pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 3 | NCT01573910 | May 2012 → Apr 2014 | bacterial conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT01298336 | Mar 2011 → Mar 2019 | pulmonary non-tuberculous mycobacterial infection | Centre Hospitalier Universitaire, Amiens | Completed | No outcome recorded |
| Phase 3 | NCT01069900 | Jul 2010 → Jan 2015 | infectious peritonitis | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01154959 | Feb 2010 → Dec 2015 | pulmonary tuberculosis | Tuberculosis Research Centre, India | Completed | No outcome recorded |
| Phase 3 | NCT00876850 | Jul 2009 → Jul 2010 | — | Paratek Pharmaceuticals Inc | Withdrawn | No outcome recorded |
| Phase 3 | NCT00828971 | Nov 2008 → Sep 2009 | infectious disease | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00759148 | Oct 2008 → Mar 2010 | bacterial conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00717561 | Feb 2008 → May 2009 | pneumonia | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00864383 | Jan 2008 → Oct 2013 | pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 3 | NCT00453349 | Jan 2007 → May 2008 | pelvic inflammatory disease | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00455806 | Jan 2007 → Feb 2008 | Helicobacter pylori infectious disease, chronic gastritis | Technical University Dresden | Unknown | No outcome recorded |
| Phase 3 | NCT00398411 | Oct 2006 → Dec 2008 | Hodgkins lymphoma, bacterial infectious disease, non-Hodgkin lymphoma, plasma cell myeloma | University of Cologne | Completed | No outcome recorded |
| Phase 3 | NCT00402727 | Sep 2006 → Jun 2008 | abscess, skin infection, ulcer disease | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00492726 | Jul 2006 → Feb 2009 | infectious disease | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00335088 | Jun 2006 → May 2007 | eye infectious disorder | HaEmek Medical Center, Israel | Unknown | No outcome recorded |
| Phase 3 | NCT00332293 | May → Dec 2006 | bacterial conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00629135 | Nov 2005 → Aug 2011 | abscess | Hannover Medical School | Completed | No outcome recorded |
| Phase 3 | NCT00331916 | Nov 2005 → May 2007 | bacterial conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00769171 | Oct 2005 → Dec 2006 | infectious peritonitis | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00492024 | Jan 2005 → Mar 2008 | sinusitis | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00473460 | Oct 2004 → Jan 2007 | chronic bronchitis | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00431678 | Jan 2004 → Jul 2005 | pneumonia | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00323219 | Jan 2004 → Dec 2012 | cellulitis | University of British Columbia | Completed | No outcome recorded |
| Phase 3 | NCT00683865 | Apr 2003 → Oct 2004 | pelvic inflammatory disease | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT01045902 | Feb 2001 → Jan 2005 | aspiration pneumonia, lung abscess | Bayer | Completed | No outcome recorded |
| Phase 435 trials | ||||||
| Phase 4 | NCT06153069 | Nov 2025 → Nov 2027 expected | tuberculosis | Huashan Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT05381194 | Dec 2022 → Dec 2027 expected | multidrug-resistant tuberculosis | Asan Medical Center | Recruiting | No outcome recorded |
| Phase 4 | NCT05398679 | Aug 2022 → Dec 2026 expected | infective endocarditis | Fundacion Clinic per a la Recerca Biomédica | Recruiting | No outcome recorded |
| Phase 4 | NCT05184491 | Oct 2021 → Feb 2022 | Helicobacter pylori infectious disease | National Liver Institute, Egypt | Unknown | No outcome recorded |
| Phase 4 | NCT03830671 | Mar 2019 → Jun 2022 | multidrug-resistant tuberculosis | Beijing Chest Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03640650 | Aug 2018 → Mar 2021 | cataract | PeriPharm | Terminated | No outcome recorded |
| Phase 4 | NCT04403334 | Jan → Apr 2018 | endophthalmitis, poisoning, senile cataract | Peregrine Eye and Laser Institute | Completed | No outcome recorded |
| Phase 4 | NCT03363295 | Jul 2017 → Dec 2019 | cataract, endophthalmitis, macular retinal edema | Federal University of Pernambuco | Completed | No outcome recorded |
| Phase 4 | NCT03237182 | Jun 2017 → Dec 2022 | multidrug-resistant tuberculosis | Centre for the AIDS Programme of Research in South Africa | Terminated | No outcome recorded |
| Phase 4 | NCT02839421 | Dec 2015 → May 2019 | periodontitis, aggressive | Facultad Nacional de Salud Publica | Unknown | No outcome recorded |
| Phase 4 | NCT01936480 | Oct 2013 → Jun 2019 | cardiac rhythm disease | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT02331823 | Jun 2013 → Dec 2015 | pulmonary tuberculosis | Shanghai Pulmonary Hospital, Shanghai, China | Unknown | No outcome recorded |
| Phase 4 | NCT01854710 | May → Jul 2013 | — | Alexza Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01860703 | Nov → Dec 2012 | — | ApoPharma | Completed | No outcome recorded |
| Phase 4 | NCT01859702 | Apr → Aug 2012 | cataract | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT02016157 | Sep 2011 → Nov 2012 | chronic periodontitis | Sri Hasanamba Dental College and Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02223702 | May 2011 → May 2012 | periodontitis, aggressive | Kocaeli University | Completed | No outcome recorded |
| Phase 4 | NCT01329250 | May 2011 → Jun 2015 | tuberculosis | University Medical Center Groningen | Terminated | No outcome recorded |
| Phase 4 | NCT01130922 | Mar → Jun 2010 | — | University Ghent | Completed | No outcome recorded |
| Phase 4 | NCT00895089 | May 2009 → Dec 2010 | liver abscess (disease) | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| Phase 4 | NCT00805558 | Feb → Dec 2009 | chronic periodontitis | Facultad Nacional de Salud Publica | Completed | No outcome recorded |
| Phase 4 | NCT00840580 | Jan → Sep 2009 | cataract | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00952796 | Jan 2009 → Dec 2010 | peritonitis | Kaohsiung Medical University Chung-Ho Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00798577 | Oct 2008 → Feb 2009 | bacterial conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00870103 | Sep 2008 → Feb 2009 | cataract | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00752947 | Sep 2008 → Mar 2010 | pneumonia | Beijing Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01302951 | Jul 2008 → Jul 2010 | flucloxacilline toxicity | University Hospital, Saarland | Completed | No outcome recorded |
| Phase 4 | NCT00656747 | Mar 2008 → Dec 2010 | chronic bronchitis | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT00564447 | Dec 2007 | bacterial infectious disease, eye infectious disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT00347828 | Jun 2006 | eye infectious disorder | Ophthalmic Consultants of Boston | Unknown | No outcome recorded |
| Phase 4 | NCT00312338 | Jun 2006 → Jun 2007 | bacterial conjunctivitis | Alcon Research | Completed | No outcome recorded |
| Phase 4 | NCT00493038 | Feb 2006 → Jan 2008 | bacterial infectious disease, sinusitis | Bayer | Terminated | No outcome recorded |
| Phase 4 | NCT00280514 | Jan 2006 → Dec 2009 | abscess | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT00668304 | Jun 2004 → Jan 2005 | maxillary sinusitis | Bayer | Completed | No outcome recorded |
| Phase 4 | NCT00665327 | Nov 2002 → Apr 2004 | pneumonia | Bayer | Completed | No outcome recorded |
| Phase not applicable15 trials | ||||||
| — | NCT07608172 | May 2026 → Jun 2028 expected | pulmonary tuberculosis | Shanghai Public Health Clinical Center | Not yet recruiting | No outcome recorded |
| — | NCT07585461 | Apr 2026 → Dec 2028 expected | AIDS-related disorder, Mycobacterium avium complex disease | Shanghai Public Health Clinical Center | Not yet recruiting | No outcome recorded |
| — | NCT07394257 | Oct 2025 → Apr 2026 overdue | corneal ulcer | Minia University | Recruiting | No outcome recorded |
| — | NCT07126639 | Sep 2025 → Sep 2027 expected | — | Wuhan Pulmonary Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07014735 | Apr 2023 → May 2026 | hyperglycemia, torsades de pointes, type 2 diabetes mellitus | Richmond Pharmacology Limited | Terminated | No outcome recorded |
| — | NCT05428683 | Dec 2020 → Aug 2021 | — | Emad Abdel Aal Saliem | Completed | No outcome recorded |
| — | NCT04187469 | Mar 2020 → Feb 2023 | pulmonary tuberculosis | Fifth Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| — | NCT02359331 | Aug 2014 → Dec 2022 | Helicobacter pylori infectious disease | Seoul National University Bundang Hospital | Terminated | No outcome recorded |
| — | NCT02373280 | Aug 2014 → Apr 2027 expected | Helicobacter pylori infectious disease | Seoul National University Bundang Hospital | Recruiting | No outcome recorded |
| — | NCT01653990 | Jul → Sep 2012 | long QT syndrome | Peking University Third Hospital | Unknown | No outcome recorded |
| — | NCT01259141 | Oct 2010 → Dec 2014 | Mycoplasma pneumoniae pneumonia | Capital Medical University | Completed | No outcome recorded |
| — | NCT02349685 | Jan 2010 → Jun 2014 | Helicobacter pylori infectious disease | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| — | NCT00466570 | Apr 2007 → ? | — | Stanford University | Withdrawn | No outcome recorded |
| — | NCT00062231 | Apr 2002 → Oct 2006 | cancer of unknown primary site, infectious disease, leukemia, myelodysplastic syndrome +5 | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | No outcome recorded |
| — | NCT00414011 | ? → Feb 2005 | corneal disorder | Walter Reed Army Medical Center | Completed | No outcome recorded |
Also used as a comparator or background therapy in 299 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04966325 Comparator | Sep → Dec 2021 | gout | LG Chem | Completed | No outcome recorded |
| Phase 0 | NCT02099240 Comparator | Mar 2014 → Nov 2018 | osteomyelitis | University of Louisville | Terminated | No outcome recorded |
| Phase 1184 trials | ||||||
| Phase 1 | NCT07708272 Comparator | Jul → Dec 2026 expected | myelofibrosis | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07513207 Comparator | Apr → Jul 2026 overdue | — | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07594847 Comparator | Mar → Sep 2026 expected | — | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07272629 Comparator | Dec 2025 → May 2026 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT07116915 Comparator | Aug 2025 → Dec 2026 expected | chronic obstructive pulmonary disease | Guangdong Hengrui Pharmaceutical Co., Ltd | Recruiting | No outcome recorded |
| Show all 184 trials opens the full record — a long page | ||||||
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04212429 Comparator | Sep 2019 → Aug 2021 | endophthalmitis | National University of Malaysia | Unknown | No outcome recorded |
| Phase 1/2 | NCT04214821 Comparator | Sep 2019 → Aug 2021 | endophthalmitis | National University of Malaysia | Unknown | No outcome recorded |
| Phase 1/2 | NCT02114684 Comparator | Nov 2013 → Jul 2017 | tuberculosis | Centre for the AIDS Programme of Research in South Africa | Completed | No outcome recorded |
| Phase 222 trials | ||||||
| Phase 2 | NCT07308938 Background | Oct 2026 → Dec 2029 expected | corneal ulcer | Vishal Jhanji | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07170800 Background | Sep 2025 → Feb 2026 overdue | multidrug-resistant tuberculosis, rifampicin-resistant tuberculosis | WestVac Biopharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05630872 Background | Feb 2024 → May 2025 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT05926466 Comparator | Sep 2023 → Aug 2024 | pulmonary tuberculosis | Michael Hoelscher | Unknown | No outcome recorded |
| Phase 2 | NCT05162625 Comparator | Dec 2021 → Dec 2022 | acute endophthalmitis | University of Campinas, Brazil | Unknown | No outcome recorded |
| Phase 2 | NCT04550832 Background | Oct 2021 → Jan 2023 | pulmonary tuberculosis | LigaChem Biosciences, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04179500 Background | Sep 2021 → Jun 2023 | multidrug-resistant tuberculosis, pulmonary tuberculosis | Global Alliance for TB Drug Development | Completed | No outcome recorded |
| Phase 2 | NCT03959566 Background | May 2021 → Sep 2022 | pulmonary tuberculosis | Michael Hoelscher | Completed | No outcome recorded |
| Phase 2 | NCT03187301 Comparator | Aug → Dec 2017 | Parkinson disease | Sumitomo Pharma America, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02903836 Comparator | Nov 2016 → Jul 2017 | bacterial pneumonia | Wockhardt | Completed | No outcome recorded |
| Phase 2 | NCT02515864 Comparator | Aug 2015 → Mar 2016 | — | Fuji Yakuhin Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01589497 Comparator | Jun 2015 → Jan 2016 | tuberculosis | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 2 | NCT02980523 Comparator | Mar 2015 → Jun 2016 | bacterial conjunctivitis | Laboratorios Sophia S.A de C.V. | Completed | No outcome recorded |
| Phase 2 | NCT02168816 Comparator | Mar 2014 → Feb 2017 | osteomyelitis | Loyola University | Terminated | No outcome recorded |
| Phase 2 | NCT02098486 Comparator | Mar 2014 → Sep 2015 | cholangitis | Kangbuk Samsung Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01928693 Comparator | Jul 2013 → May 2014 | corneal ulcer | Cornea Consultants Of Nashville | Terminated | No outcome recorded |
| Phase 2 | NCT01839279 Comparator | Apr 2013 → Feb 2014 | — | Acorda Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT01785186 Comparator | Apr 2013 → Sep 2014 | pulmonary tuberculosis | Michael Hoelscher | Completed | No outcome recorded |
| Phase 2 | NCT01944774 Comparator | Mar → Dec 2013 | pneumonia | TaiGen Biotechnology Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01198626 Comparator | Oct 2010 → Oct 2011 | bacterial pneumonia | Furiex Pharmaceuticals, Inc | Terminated | No outcome recorded |
| Phase 2 | NCT00579020 Comparator | Dec 2007 → Feb 2009 | keratitis | Alcon Research | Terminated | No outcome recorded |
| Phase 2 | NCT00578773 Comparator | Nov 2007 → Jan 2009 | otitis media | Alcon Research | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT03244072 Comparator | Jun 2026 → Oct 2030 expected | endophthalmitis | Jason Ahee, M.D. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05255107 Background | Mar 2022 → Nov 2023 | corneal ulcer | Peschke GmbH | Unknown | No outcome recorded |
| Phase 2/3 | NCT02454205 Comparator | Nov 2015 → Dec 2020 | extensively drug-resistant tuberculosis, multidrug-resistant tuberculosis | University of Cape Town | Completed | No outcome recorded |
| Phase 335 trials | ||||||
| Phase 3 | NCT07305987 Comparator | Oct 2025 → Jun 2026 overdue | cataract | Laboratorios Sophia S.A de C.V. | Recruiting | No outcome recorded |
| Phase 3 | NCT06905522 Comparator | Jun 2025 → Jan 2029 expected | pulmonary tuberculosis | Shenzhen Third People's Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06271772 Background | Jul 2024 → Jun 2026 overdue | keratitis | University of California, San Francisco | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05902221 Comparator | May 2024 → May 2028 expected | periprosthetic joint infection | Centre Hospitalier Universitaire de Nice | Recruiting | No outcome recorded |
| Phase 3 | NCT06081361 Background | Dec 2023 → Oct 2026 expected | pulmonary tuberculosis, rifampicin-resistant tuberculosis | Beijing Chest Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06162286 Comparator | Nov 2023 → Jan 2025 | bacterial pneumonia | Zai Lab | Unknown | No outcome recorded |
| Phase 3 | NCT05454345 Comparator | Oct 2022 → Jun 2025 | pulmonary tuberculosis | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
| Phase 3 | NCT04722978 Comparator | Apr 2021 → Jun 2026 overdue | triple-negative breast carcinoma | Sun Yat-sen University Cancer Center | Recruiting | No outcome recorded |
| Phase 3 | NCT04779242 Comparator | Feb 2021 → Mar 2024 | bacterial pneumonia | Paratek Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 3 | NCT04097730 Background | Sep 2020 → May 2024 | keratitis | Thomas M. Lietman | Completed | No outcome recorded |
| Phase 3 | NCT05863858 Comparator | Jun 2020 → Dec 2021 | Helicobacter pylori infectious disease | Iyad Naeem Muhammad, PhD | Completed | No outcome recorded |
| Phase 3 | NCT02770729 Comparator | Jan 2017 → Feb 2018 | endophthalmitis | University of Campinas, Brazil | Terminated | No outcome recorded |
| Phase 3 | NCT02679573 Comparator | Dec 2016 → Jul 2018 | bacterial pneumonia | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02813694 Comparator | Aug 2016 → Jan 2018 | — | Nabriva Therapeutics AG | Completed | No outcome recorded |
| Phase 3 | NCT02717871 Comparator | Mar 2016 → Oct 2020 | keratitis | University Hospital, Geneva | Completed | No outcome recorded |
| Phase 3 | NCT02409290 Comparator | Mar 2016 → May 2022 | multidrug-resistant tuberculosis | IUATLD, Inc | Completed | No outcome recorded |
| Phase 3 | NCT02531438 Comparator | Nov 2015 → Feb 2017 | bacterial pneumonia | Paratek Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 3 | NCT02559310 Comparator | Sep 2015 → Apr 2017 | — | Nabriva Therapeutics AG | Completed | No outcome recorded |
| Phase 3 | NCT01515826 Comparator | Mar → Oct 2014 | cataract | Alcon Research | Withdrawn | No outcome recorded |
| Phase 3 | NCT01968733 Comparator | Nov 2013 → Jul 2015 | bacterial pneumonia | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01756339 Comparator | Dec 2012 → Oct 2014 | bacterial pneumonia | Melinta Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01658020 Comparator | Aug 2012 → Jan 2014 | chronic obstructive pulmonary disease | Dong Wha Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01603030 Comparator | Jun → Aug 2012 | eye infectious disorder | Adapt Produtos Oftalmológicos Ltda. | Unknown | No outcome recorded |
| Phase 3 | NCT01398072 Comparator | Dec 2011 → Jan 2013 | chronic obstructive pulmonary disease | University College, London | Unknown | No outcome recorded |
| Phase 3 | NCT01055145 Comparator | Mar 2010 → Jul 2012 | tuberculosis | Seoul National University Hospital | Terminated | No outcome recorded |
| Phase 3 | NCT01071902 Comparator | Feb 2010 → Oct 2011 | otitis media | Alcon Research | Terminated | No outcome recorded |
| Phase 3 | NCT00865280 Comparator | Apr 2009 → Apr 2010 | skin infection | Paratek Pharmaceuticals Inc | Terminated | No outcome recorded |
| Phase 3 | NCT00732446 Comparator | Aug → Dec 2008 | blepharitis, conjunctivitis, keratitis | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 3 | NCT00750633 Comparator | Jun 2008 → Jan 2009 | acute otitis externa | Alcon Research | Completed | No outcome recorded |
| Phase 3 | NCT00534287 Comparator | Oct 2007 → Apr 2010 | infectious disease with sepsis | Competence Network Sepsis | Completed | No outcome recorded |
| Phase 3 | NCT00447304 Background | Oct 2006 → Nov 2010 | acute cholecystitis | Heidelberg University | Completed | No outcome recorded |
| Phase 3 | NCT00348348 Comparator | Jun 2006 → Jul 2007 | bacterial conjunctivitis | Bausch & Lomb Incorporated | Completed | No outcome recorded |
| Phase 3 | NCT00324324 Comparator | May 2006 → Apr 2007 | breast cancer, gestational trophoblastic neoplasm, infectious disease, leukemia +6 | OHSU Knight Cancer Institute | Terminated | No outcome recorded |
| Phase 3 | NCT00254566 Comparator | Feb 2006 → Aug 2008 | chronic bronchitis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00579189 Comparator | Jan 2006 → Jan 2009 | otitis media | Alcon Research | Completed | No outcome recorded |
| Phase 434 trials | ||||||
| Phase 4 | NCT07276802 Comparator | Apr → Dec 2026 expected | cataract | Research Insight LLC | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07212803 Comparator | Nov 2025 → Mar 2026 overdue | — | University of the Pacific | Recruiting | No outcome recorded |
| Phase 4 | NCT05977868 Background | Aug 2023 → Feb 2025 | digestive system infectious disorder | West Virginia University | Terminated | No outcome recorded |
| Phase 4 | NCT06785090 Background | May 2023 → Jan 2024 | cataract, cystoid macular edema | Inas Abd | Completed | No outcome recorded |
| Phase 4 | NCT05400369 Comparator | Aug 2022 → Sep 2024 | chronic obstructive pulmonary disease | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 4 | NCT05331664 Comparator | Jul 2022 → Jul 2026 overdue | rhegmatogenous retinal detachment | Massachusetts Eye and Ear Infirmary | Recruiting | No outcome recorded |
| Phase 4 | NCT05079854 Comparator | Oct 2021 → Nov 2022 | corneal disorder, endophthalmitis | Federal University of São Paulo | Unknown | No outcome recorded |
| Phase 4 | NCT05046132 Comparator | Aug 2021 → Apr 2022 | — | Rhythm Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT04750655 Comparator | Mar 2021 → Aug 2023 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT03609099 Comparator | Feb 2019 → Nov 2020 | pneumonia | David Garcia Cinca | Unknown | No outcome recorded |
| Phase 4 | NCT03634852 Comparator | Oct 2016 → Feb 2018 | endophthalmitis | Suzan A Rattan | Completed | No outcome recorded |
| Phase 4 | NCT02819908 Comparator | Sep 2015 → Apr 2016 | uveal disorder | Eye Center of North Florida | Completed | No outcome recorded |
| Phase 4 | NCT02515045 Comparator | Jan 2015 → Mar 2016 | cataract | Carolina Eyecare Physicians, LLC | Completed | No outcome recorded |
| Phase 4 | NCT01296542 Comparator | May 2011 → Jan 2013 | cataract | Bucci Laser Vision Institute | Completed | No outcome recorded |
| Phase 4 | NCT01296191 Comparator | May 2011 → Jan 2013 | cataract | Frank A. Bucci, Jr., M.D. | Completed | No outcome recorded |
| Phase 4 | NCT01455233 Comparator | Sep 2010 → Feb 2011 | cataract, corneal disorder | Ophthalmology Consultants, Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT01091493 Comparator | Jul 2010 → Jul 2018 | chronic obstructive pulmonary disease | Fundacion Clinic per a la Recerca Biomédica | Completed | No outcome recorded |
| Phase 4 | NCT01799356 Comparator | Jun 2010 → Mar 2013 | pelvic inflammatory disease | Istanbul Bakirkoy Maternity and Children Diseases Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00924729 Comparator | Sep → Oct 2009 | cataract | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT00874887 Comparator | Mar → Sep 2009 | — | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00887276 Comparator | Nov 2008 → Jan 2011 | — | University of Ulm | Terminated | No outcome recorded |
| Phase 4 | NCT00764582 Comparator | Sep 2008 → Mar 2009 | — | Santen Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT00690313 Comparator | Aug 2008 → Apr 2011 | — | Illinois Retina Associates | Completed | No outcome recorded |
| Phase 4 | NCT02136875 Background | Jul 2008 → Aug 2010 | chronic obstructive pulmonary disease | McGill University Health Centre/Research Institute of the McGill University Health Centre | Completed | No outcome recorded |
| Phase 4 | NCT00758199 Comparator | Jul 2008 → Jan 2010 | cataract | Bp Consulting, Inc | Completed | No outcome recorded |
| Phase 4 | NCT00703313 Comparator | May → Jun 2008 | — | Santen Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00575367 Comparator | Mar → Oct 2008 | bacterial infectious disease, eye infectious disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT00630019 Comparator | Feb → Oct 2008 | cataract | Santen Inc. | Completed | No outcome recorded |
| Phase 4 | NCT00575380 Comparator | Dec 2007 → Jun 2008 | bacterial infectious disease, cataract, eye infectious disorder | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT00464438 Comparator | Jun 2007 → Sep 2008 | bacterial conjunctivitis | Allergan | Completed | No outcome recorded |
| Phase 4 | NCT00581542 Comparator | Mar 2007 → Mar 2009 | conjunctivitis | University of Rochester | Completed | No outcome recorded |
| Phase 4 | NCT00324168 Comparator | Sep 2006 → Feb 2011 | corneal infection, corneal ulcer | Thomas M. Lietman | Completed | No outcome recorded |
| Phase 4 | NCT01792700 Comparator | Jan 2003 → Dec 2010 | Helicobacter pylori infectious disease | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00407017 Background | — | cataract | Innovative Medical | Completed | No outcome recorded |
| Phase not applicable16 trials | ||||||
| — | NCT06210269 Comparator | Jan 2024 → Dec 2025 overdue | appendicitis | Turku University Hospital | Not yet recruiting | No outcome recorded |
| — | NCT05881187 Comparator | Jun 2023 → Apr 2024 | keratitis | Sohag University | Unknown | No outcome recorded |
| — | NCT05027893 Comparator | Jun 2019 → Dec 2023 | bacterial infectious disease, poisoning | University of Novi Sad | Unknown | No outcome recorded |
| — | NCT03868657 Comparator | Jan → Aug 2019 | hypoglycemia, long QT syndrome | Signe Torekov | Completed | No outcome recorded |
| — | NCT03604848 Comparator | Aug 2018 → Aug 2024 | multidrug-resistant tuberculosis | Huashan Hospital | Unknown | No outcome recorded |
| — | NCT03257423 Comparator | Apr 2017 → Dec 2022 | appendicitis | Turku University Hospital | Unknown | No outcome recorded |
| — | NCT03236961 Comparator | Apr 2017 → Nov 2018 overdue | appendicitis | Turku University Hospital | Active not recruiting | No outcome recorded |
| — | NCT02680080 Comparator | Dec 2016 → Jun 2018 | long QT syndrome | Tel-Aviv Sourasky Medical Center | Completed | No outcome recorded |
| — | NCT02800785 Comparator | May 2016 → Mar 2020 | appendicitis | University of Washington | Completed | No outcome recorded |
| — | NCT02787057 Comparator | Nov 2012 → Apr 2016 | infectious peritonitis | Peking University First Hospital | Completed | No outcome recorded |
| — | NCT01761214 Comparator | Sep 2012 → Dec 2023 | bronchiectasis | Guangzhou Institute of Respiratory Disease | Unknown | No outcome recorded |
| — | NCT01876316 Comparator | Nov 2011 → Sep 2012 | — | Inje University | Completed | No outcome recorded |
| — | NCT01577342 Comparator | Nov 2010 → Dec 2011 | age-related macular degeneration | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Completed | No outcome recorded |
| — | NCT00892918 Comparator | Jun 2009 → Jun 2010 | pterygium | Meir Medical Center | Unknown | No outcome recorded |
| — | NCT00331084 Comparator | Apr → Dec 2006 | — | Federal University of São Paulo | Completed | No outcome recorded |
| — | NCT00330824 Comparator | Apr → Sep 2006 | — | Federal University of São Paulo | Completed | No outcome recorded |
Evidence & citations 38 cited values
Every value below carries the sentence it was read from. 574 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Moxifloxacin | “Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane Ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon...” NCT05331859 ↗544“This randomized, three treatment, three period, six sequence crossover study with placebo, a positive control (moxifloxacin 400 mg) and tafamidis (400 mg, to achieve a...” PMID 25546001 ↗ Jun 2015 “This therapy is usually one of the following oral medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv)...” NCT02168816 ↗ “The objective of this study is to analyze the efficacy of a new regimen using Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin for 24 weeks or Bedaquiline, Pretomanid,...” NCT05381194 ↗ “Fourteen-day esomeprazole, tripotassium dicitrate bismuthate, metronidazole and tetracycline (EBMT) therapy or esomeprazole, moxifloxacin and amoxicillin (MEA) therapy was...” PMID 26452405 ↗ Oct 2015 “This study aims to evaluate whether adding a fluoroquinolone (levofloxacin or moxifloxacin) to the standard triple therapy improves early clinical outcomes in HIV-infected...” NCT07585461 ↗ “Experimental arms are seven oral regimens with a five-drug combination of the following: bedaquiline, linezolid, a fluoroquinolone (moxifloxacin or levofloxacin), cycloserine,...” NCT05081401 ↗ “Bedaquiline 400 mg once daily for 2 weeks then 200 mg thrice a week for 24 weeks + Pretomanid 200 mg QD for 26 weeks + Linezolid 600 mg once daily for 26 weeks + Moxifloxacin...” NCT07209761 ↗ “The fluroquinolones employed in the present study are referred to as oral levofloxacin (500mg q.d.), moxifloxacin (400mg, q.d.) and ciprofloxacin (500mg, b.i.d.).” NCT01761214 ↗ “using regimens containing isoniazid (INH \[H\]), rifampin (RIF \[R\]), pyrazinamide (PZA \[Z\]), moxifloxacin (MXF \[M\]), and ethambutol (EMB \[E\]).” NCT02371681 ↗ “The "conventional" topical medication regimen will include prednisolone acetate 1% QID, ketorolac 0.5% QID , and moxifloxacin 0.5% topical drops QID.” NCT07276802 ↗ “Giving antibiotics, such as moxifloxacin, may help prevent bacterial infections in patients who have recently undergone donor stem cell transplant.” NCT00324324 ↗ “8 weeks of daily isoniazid, rifapentine, moxifloxacin and pyrazinamide, followed by 9 weeks of daily isoniazid, rifapentine and moxifloxacin.” NCT07608172 ↗ “Fluoroquinolone topical antibiotic (Moxifloxacin, Vigamox) and topical steroid (Prednisolone Acetate Ophthalmic Suspension, Pred Forte)” NCT02625467 ↗ “Single used, pre-mixed, centrally compounded injectable that contains 15 mg/ml of triamcinolone acetonide and 1 mg/ml of moxifloxacin.” NCT03640650 ↗ “Standard Of Care: Moxifloxacin 0.5% eyedrop therapy every 1 hour (q1h) while awake; to be tapered at treating physician's discretion.” NCT05255107 ↗ “The abbreviation of the name of the 3 drugs in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）” NCT03830671 ↗ “8 weeks of isoniazid, pyrazinamide, rifapentine, and moxifloxacin, followed by 9 weeks of isoniazid, rifapentine and moxifloxacin” NCT04856644 ↗ “1 tablet of Izilox® (400 mg moxifloxacin) in fed condition following a high-fat/low-Kcal meal, on Day 4 morning” NCT01103830 ↗ “moxifloxacin 0.5% every one hour for 48 hours while awake and then every 2 hours until re-epithelialization” NCT00324168 ↗ “Patients will be treated with antibiotics (Cefazolin, Tobramycin or Moxifloxacin) we per treating physician” NCT07308938 ↗ “For gram negative treatment: Moxifloxacin 400mg tablets and pre-mixed 400mg IV infusion solution” NCT00876850 ↗ “Naïve patients will receive Moxifloxacin, nitazoxanide, doxycycline and Lansoprazole for 14 days” NCT05184491 ↗ “The fluoroquinolone antibiotics included ciprofloxacin, levofloxacin, and moxifloxacin.” NCT04879030 ↗ “daily rifapentine (R) and moxifloxacin (M) plus isoniazid (H) and pyrazinamide (P)” NCT05630872 ↗ “high-dose rifapentine (P), isoniazid (H), pyrazinamide (Z), and moxifloxacin (M)” NCT06153069 ↗ “Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, \>70kg 800mg daily” NCT03604848 ↗ “Treatment D: 400 mg oral moxifloxacin on Day 1 and placebo patch on Day 3” NCT00890565 ↗ “Moxifloxacin, omeprazole sodium bicarbonate, nitazoxanide, doxycyclin” NCT03491995 ↗ “metronidazole, moxifloxacin, rifampin, trimethoprim-sulfamethoxazole” NCT05977868 ↗ “bedaquiline, pretomanid, linezolid, moxifloxacin, and pyrazinamide” NCT07227779 ↗ “moxifloxacin, pasiniazid, rifabutin, ethambutol, and pyrazinamide” PMID 29519716 ↗ Mar 2018 “rifampicin 35 mg/kg, with or without moxifloxacin 400 mg” PMID 41612490 ↗ Jan 2026 “Moxifloxacin Hydrochloride 0.5% Ophthalmic Solution” NCT01928693 ↗ “levofloxacin, moxifloxacin, ofloxacin, gatifloxacin” NCT03237182 ↗ “Using Moxifloxacin (Avelox®) as a positive control” NCT00887770 ↗ “Moxifloxacin 0.5% and Dexamethasone Phosphate 0.1%” NCT06352541 ↗ “Vigamox Ophthalmic Solution (Moxifloxacin 5mg/mL)” NCT00798577 ↗ “a single oral (PO) moxifloxacin 400 mg dose” NCT01812538 ↗ “moxifloxacin (Izilox daily dose 400mg)” NCT05821478 ↗ “Moxifloxacin (M): 400 mg qd.” NCT07170800 ↗ “Moxifloxacin (MFX):” NCT07268664 ↗ “Drug: Moxifloxacin” NCT01017731 ↗ “Moxifloxacin” NCT00713336 ↗ “Moxifloxacin” NCT02099240 ↗ |
| Known as | AL-15469A | “AL-15469A for the Treatment of Bacterial Conjunctivitis” NCT00331916 ↗ |
| Known as | Avalox | “Drug: Moxifloxacin (Avalox®)” NCT01965431 ↗1“Moxifloxacin (Avalox®)” NCT02172144 ↗ |
| Known as | Avalox (moxifloxacin) | “Avalox® (moxifloxacin)” NCT00534287 ↗ |
| Known as | avelox | “Moxifloxacin (Avelox, Bayer): will be administered to patients per os as tablet as single or multiple doses of 400 mg.” NCT00280514 ↗30“Moxifloxacin (Avelox) is a drug with a known potential to create a mild QTc interval prolongation” NCT01756495 ↗ “Avelox (Moxifloxacin, BAY12-8039), 400 mg capsules orally once daily for 5 days every 8 weeks” NCT00473460 ↗ “Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days” NCT00453349 ↗ “1\) Purulent exacerbation - Antibiotic: Avelox 400 mg daily for 5 days.” NCT02136875 ↗ “Avelox (moxifloxacin), an anti-biotic approved for use by the FDA” NCT00158093 ↗ “Using Open-label Moxifloxacin (Avelox®) as a Positive Control” NCT01290900 ↗ “Moxifloxacin (Avelox®) is administered as positive control.” NCT01516255 ↗ “either Avelox (moxifloxacin hydrochloride) or placebo” NCT01928914 ↗ “Using Moxifloxacin (Avelox®) as a Positive Control” NCT01265641 ↗ “Moxifloxacin, avelox® 400 mg qd 7 days (D1-D7)” NCT02373280 ↗ “moxifloxacin hydrochloride (Avelox®)” NCT01090661 ↗ “Moxifloxacin (Avelox, BAY12-8039)” NCT00492726 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT00683865 ↗ “Moxifloxacin (Avelox, BAY12-8039)” NCT00493038 ↗ “Moxifloxacin (Avelox, BAY12-8039)” NCT01073891 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT00828971 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT00668304 ↗ “Moxifloxacin (Avelox, BAY12-8039)” NCT00402727 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT01045902 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT00769171 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT00656747 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT00717561 ↗ “Moxifloxacin (Avelox, BAY12-8039)” NCT01069900 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT00431678 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT00665327 ↗ “Moxifloxacin (Avelox, BAY12-8039)” NCT00492024 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT01014247 ↗ “Moxifloxacin (Avelox, BAY12-8039)” NCT01049022 ↗ “Moxifloxacin (Avelox)” NCT04818229 ↗ |
| Known as | Avelox i.v. | ChEMBL registry synonym — accepted as the source's own label CHEMBL32 ↗ |
| Known as | Avelox(TM) | “oral moxifloxacin 400mg film coated tablets - Avelox(TM)” NCT03709927 ↗ |
| Known as | BAY12-8039 | “Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days.” NCT00402727 ↗19“Avelox (Moxifloxacin, BAY12-8039), 400 mg capsules orally once daily for 5 days every 8 weeks” NCT00473460 ↗ “Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days” NCT00453349 ↗ “Moxifloxacin (Avelox, BAY12-8039)” NCT00492726 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT00828971 ↗ “Moxifloxacin (Avelox, BAY12-8039)” NCT01073891 ↗ “Moxifloxacin (Avelox, BAY12-8039)” NCT00493038 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT01045902 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT00683865 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT00668304 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT00717561 ↗ “Moxifloxacin (Avelox, BAY12-8039)” NCT01069900 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT00656747 ↗ “Moxifloxacin (Avelox, BAY12-8039)” NCT00492024 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT00665327 ↗ “Moxifloxacin (Avelox, BAY12-8039)” NCT01049022 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT00431678 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT00769171 ↗ “Avelox (Moxifloxacin, BAY12-8039)” NCT01014247 ↗ “Moxifloxacin (BAY12-8039)” NCT00310596 ↗ |
| Known as | Izilox | “then one 400 mg moxifloxacin tablet (Izilox®, Bayer Pharmaceuticals Corporation) administered orally on Day 14” NCT02091310 ↗2“1 tablet of Izilox® (400 mg moxifloxacin) on Day 4 morning.” NCT01103830 ↗ “moxifloxacin (Izilox daily dose 400mg)” NCT05821478 ↗ |
| Known as | MFLX | “In vitro studies have suggested the corneal cytotoxicity of third-generation fluoroquinolone levofloxacin (LVFX) and fourth-generation fluoroquinolone moxifloxacin...” PMID 21060669 ↗ Oct 2010 |
| Known as | MFX | “The abbreviation of the name of the 3 drugs in the regimen is explained as follows: PZA-pyrazinamide，Am-Amikacin，Mfx-moxifloxacin）” NCT03830671 ↗3“A six - month regimen containing bedaquiline (BDQ), pretomanid (Pa), linezolid (LZD), and moxifloxacin (MFX)” NCT07126639 ↗ “Regimen A (bedaquiline [Bdq]+linezolid [Lzd]+moxifloxacin [Mfx]+cycloserine [Cs]+pyrazinamide [Pza])” PMID 37567554 ↗ Aug 2023 “Moxifloxacin (MFX):” NCT07268664 ↗ |
| Known as | Minims | ChEMBL registry synonym — accepted as the source's own label CHEMBL32 ↗ |
| Known as | MOX | “The interventions are Scaling and Root Planing (SRP) combined with systemically administered moxifloxacin (MOX) 400 mg, once daily for 7 days.” NCT02839421 ↗ |
| Known as | Moxeza | “An alternative formulation of 0.5% moxifloxacin ophthalmic solution (Moxeza, MOXI-AF, Alcon Laboratories, Inc., Fort Worth, TX, USA) containing xanthan gum to prolong retention...” PMID 21681652 ↗ Jun 2011 |
| Known as | MOXI-AF | “An alternative formulation of 0.5% moxifloxacin ophthalmic solution (Moxeza, MOXI-AF, Alcon Laboratories, Inc., Fort Worth, TX, USA) containing xanthan gum to prolong retention...” PMID 21681652 ↗ Jun 2011 |
| Known as | Moxifloxacin (as hydrochloride) | ChEMBL registry synonym — accepted as the source's own label CHEMBL32 ↗ |
| Known as | Moxifloxacin (Avelox) | “Moxifloxacin (Avelox)” NCT02168816 ↗1“moxifloxacin (Avelox)” NCT01761214 ↗ |
| Known as | Moxifloxacin 400 mg (Avelox, Tablet) | “Moxifloxacin 400 mg (Avelox, Tablet)” NCT01871701 ↗ |
| Known as | Moxifloxacin AF | “Moxifloxacin AF Ophthalmic Solution compared to Moxifloxacin AF Vehicle” NCT00759148 ↗ |
| Known as | Moxifloxacin hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL32 ↗ |
| Known as | moxifloxacin hydrochloride | “Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.” NCT04214821 ↗18“Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.” NCT04212429 ↗ “One 400 mg moxifloxacin tablet (AVELOX®, moxifloxacin hydrochloride, Bayer Pharmaceuticals Corporation) will be administered orally on the morning of Day 1” NCT01986894 ↗ “A single, commercially-available, film-coated, 400-mg tablet of moxifloxacin hydrochloride will be administered orally with 120 mL of tap water.” NCT03613649 ↗ “one such compound includes triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin (TriMoxiVanc).” NCT02819908 ↗ “Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose” NCT02910635 ↗ “either Avelox (moxifloxacin hydrochloride) or placebo” NCT01928914 ↗ “0.5% moxifloxacin hydrochloride ophthalmic solution” NCT00630019 ↗ “receive oral moxifloxacin hydrochloride once daily” NCT00324324 ↗ “Avelox (moxifloxacin hydrochloride) tablet” NCT01148537 ↗ “VIGAMOX {0.5% moxifloxacin hydrochloride}” NCT06681688 ↗ “moxifloxacin hydrochloride (Avelox®)” NCT01090661 ↗ “Drug: moxifloxacin hydrochloride” NCT00824070 ↗ “Drug: moxifloxacin hydrochloride” NCT01910415 ↗ |
| Known as | Moxifloxacin hydrochloride (Vigamox) | “Moxifloxacin hydrochloride (Vigamox)” NCT00758199 ↗ |
| Known as | MOXIFLOXACIN HYDROCHLORIDE HYDRATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL32 ↗ |
| Known as | moxifloxacin tablets | “moxifloxacin tablets” NCT02331823 ↗ |
| Known as | Moxifloxacine | ChEMBL registry synonym — accepted as the source's own label CHEMBL32 ↗ |
| Known as | Moxifloxacino | ChEMBL registry synonym — accepted as the source's own label CHEMBL32 ↗ |
| Known as | Moxivig | ChEMBL registry synonym — accepted as the source's own label CHEMBL32 ↗ |
| Known as | MXF | “The aim of the study is to provide data on the pharmacokinetics (PK) of moxifloxacin (MXF) in serum and liver tissue of patients undergoing liver resection due to primary or...” NCT01302951 ↗6“We evaluated the efficacies of oral prophylactic treatment with amoxicillin (AMX), clindamycin (CLI), and moxifloxacin (MXF) in the prevention of bacteremia following dental...” PMID 16940094 ↗ Sep 2006 “BACKGROUND: This study was designed to evaluate primarily the safety and also the efficacy of moxifloxacin (MXF) in children with complicated intra-abdominal infections (cIAIs).” PMID 29356761 ↗ Aug 2018 “Levofloxacin (LFX) and moxifloxacin (MXF) are the two most frequently recommended fluoroquinolones for treatment of patients with multidrug-resistant tuberculosis (MDR-TB).” PMID 23927582 ↗ Oct 2013 “Moxifloxacin (MXF) is a synthetic fluoroquinolone antibiotic.” NCT00816426 ↗ “intravenous/oral moxifloxacin (MXF, N = 110) 400 mg q.d.” PMID 23180507 ↗ Nov 2012 “moxifloxacin (MXF \[M\])” NCT02371681 ↗ |
| Known as | NSC-758875 | ChEMBL registry synonym — accepted as the source's own label CHEMBL32 ↗ |
| Known as | PRO-231 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06363292 ↗ |
| Known as | Vigamox | “Topical moxifloxacin 0.5% (Vigamox; Alcon Laboratories) four times per day, artificial tears (Systane Ultra; Alcon) every two hours, Dexamethasone 0.1% (Maxidex; Alcon...” NCT05331859 ↗13“Phacoemulsification surgery patients in the experimental group (Group A) received a 0.03 mL intracameral injection of undiluted moxifloxacin from a sealed bottle immediately...” PMID 32818353 ↗ Jan 2021 “The aim of this study is to evaluate the efficacy and safety of the use of topical moxifloxacin 0.5% ophthalmic solution (Vigamox®) in the prophylaxis of acute endophthalmitis...” NCT05162625 ↗ “About 20 patients treated by Moxifloxacin ophthalmic solution 0.5% (Vigamox) 4 times a day (one drop each time) after pterygium excision with Mitomycin C application.” NCT00892918 ↗ “The study evaluates the use of intracameral Moxifloxacin 0.5% (Vigamox®) as prophylaxis in cases of endophthalmitis after open ocular trauma;” NCT05079854 ↗ “Fluoroquinolone topical antibiotic (Moxifloxacin, Vigamox) and topical steroid (Prednisolone Acetate Ophthalmic Suspension, Pred Forte)” NCT02625467 ↗ “Vigamox (moxifloxacin hydrochloride ophthalmic solution)” NCT00575367 ↗ |
| Known as | Vigamox Ophthalmic Solution | “Vigamox Ophthalmic Solution (Moxifloxacin 5mg/mL)” NCT00798577 ↗ |
| Known as | Vigamox(moxifloxacin hydrochloride ophthalmic solution) | “Vigamox(moxifloxacin hydrochloride ophthalmic solution)” NCT00575380 ↗ |
| Known as | VIGAMOXI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06363292 ↗ |
| Known as | Zimoxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL32 ↗ |
| Action | Inhibit | “It inhibits bacterial topoisomerase II (DNA gyrase)” NCT00816426 ↗ |
| Modality | Small molecule | “4th generation fluoroquinolones” NCT00414011 ↗ |
| Route | Oral | “This double-blind, multicenter trial compared the efficacy and safety of a single daily oral dose of moxifloxacin with oral combination therapy” PMID 23358983 ↗ Jan 2013 |